New role of mechanical assist device as bridge to transplant: USA perspective

Ambreen Mohamed, Natasha Mehta, Howard J. Eisen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review Cardiac transplant remains the gold standard of care for patients with end-stage heart failure. Unfortunately, due to the limited availability of donor hearts in the United States, not all eligible candidates are able to be transplanted. Since the introduction of mechanical assist devices for the treatment of advanced heart failure, patients gain a significant survival benefit while awaiting transplant. With rapidly evolving technology, it is important to appreciate the advances in the current use of mechanical assist devices. Recent findings Following a comprehensive analysis of novel therapies in end-stage heart failure, there is an enhancement in quality of life and life expectancy following implantation of left ventricular (LV) assist devices (LVADs). When implanted in suitable patients as bridge-to-transplant or 'destination therapy', recipients demonstrate superior outcomes and survival compared with those who remain on optimal medical therapy. Summary The use of LV assist devices (LVADs) as bridge to transplantation has gained popularity over the last decade. It is recognized as an integral treatment modality in end-stage heart failure to those awaiting heart transplantation. When implanted in the appropriately chosen patient, it is superior to medical treatment alone and has shown noninferiority to heart transplantation while allowing for optimal functional status and preservation of end organ function.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
JournalCurrent Opinion in Organ Transplantation
Volume22
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Transplants
Equipment and Supplies
Heart Failure
Heart-Assist Devices
Heart Transplantation
Therapeutics
Organ Preservation
Survival
Standard of Care
Life Expectancy
Transplantation
Quality of Life
Tissue Donors
Technology

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation

Cite this

@article{33657112f9714f119ea7900425edb525,
title = "New role of mechanical assist device as bridge to transplant: USA perspective",
abstract = "Purpose of review Cardiac transplant remains the gold standard of care for patients with end-stage heart failure. Unfortunately, due to the limited availability of donor hearts in the United States, not all eligible candidates are able to be transplanted. Since the introduction of mechanical assist devices for the treatment of advanced heart failure, patients gain a significant survival benefit while awaiting transplant. With rapidly evolving technology, it is important to appreciate the advances in the current use of mechanical assist devices. Recent findings Following a comprehensive analysis of novel therapies in end-stage heart failure, there is an enhancement in quality of life and life expectancy following implantation of left ventricular (LV) assist devices (LVADs). When implanted in suitable patients as bridge-to-transplant or 'destination therapy', recipients demonstrate superior outcomes and survival compared with those who remain on optimal medical therapy. Summary The use of LV assist devices (LVADs) as bridge to transplantation has gained popularity over the last decade. It is recognized as an integral treatment modality in end-stage heart failure to those awaiting heart transplantation. When implanted in the appropriately chosen patient, it is superior to medical treatment alone and has shown noninferiority to heart transplantation while allowing for optimal functional status and preservation of end organ function.",
author = "Ambreen Mohamed and Natasha Mehta and Eisen, {Howard J.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1097/MOT.0000000000000418",
language = "English (US)",
volume = "22",
pages = "231--235",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

New role of mechanical assist device as bridge to transplant : USA perspective. / Mohamed, Ambreen; Mehta, Natasha; Eisen, Howard J.

In: Current Opinion in Organ Transplantation, Vol. 22, No. 3, 01.06.2017, p. 231-235.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New role of mechanical assist device as bridge to transplant

T2 - USA perspective

AU - Mohamed, Ambreen

AU - Mehta, Natasha

AU - Eisen, Howard J.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose of review Cardiac transplant remains the gold standard of care for patients with end-stage heart failure. Unfortunately, due to the limited availability of donor hearts in the United States, not all eligible candidates are able to be transplanted. Since the introduction of mechanical assist devices for the treatment of advanced heart failure, patients gain a significant survival benefit while awaiting transplant. With rapidly evolving technology, it is important to appreciate the advances in the current use of mechanical assist devices. Recent findings Following a comprehensive analysis of novel therapies in end-stage heart failure, there is an enhancement in quality of life and life expectancy following implantation of left ventricular (LV) assist devices (LVADs). When implanted in suitable patients as bridge-to-transplant or 'destination therapy', recipients demonstrate superior outcomes and survival compared with those who remain on optimal medical therapy. Summary The use of LV assist devices (LVADs) as bridge to transplantation has gained popularity over the last decade. It is recognized as an integral treatment modality in end-stage heart failure to those awaiting heart transplantation. When implanted in the appropriately chosen patient, it is superior to medical treatment alone and has shown noninferiority to heart transplantation while allowing for optimal functional status and preservation of end organ function.

AB - Purpose of review Cardiac transplant remains the gold standard of care for patients with end-stage heart failure. Unfortunately, due to the limited availability of donor hearts in the United States, not all eligible candidates are able to be transplanted. Since the introduction of mechanical assist devices for the treatment of advanced heart failure, patients gain a significant survival benefit while awaiting transplant. With rapidly evolving technology, it is important to appreciate the advances in the current use of mechanical assist devices. Recent findings Following a comprehensive analysis of novel therapies in end-stage heart failure, there is an enhancement in quality of life and life expectancy following implantation of left ventricular (LV) assist devices (LVADs). When implanted in suitable patients as bridge-to-transplant or 'destination therapy', recipients demonstrate superior outcomes and survival compared with those who remain on optimal medical therapy. Summary The use of LV assist devices (LVADs) as bridge to transplantation has gained popularity over the last decade. It is recognized as an integral treatment modality in end-stage heart failure to those awaiting heart transplantation. When implanted in the appropriately chosen patient, it is superior to medical treatment alone and has shown noninferiority to heart transplantation while allowing for optimal functional status and preservation of end organ function.

UR - http://www.scopus.com/inward/record.url?scp=85018679960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018679960&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000418

DO - 10.1097/MOT.0000000000000418

M3 - Review article

C2 - 28441157

AN - SCOPUS:85018679960

VL - 22

SP - 231

EP - 235

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 3

ER -